The North America Specialty Generics Market should witness market growth of 9.0% CAGR during the forecast period (2023-2030).
The complex or high-end specialty generics are generic equivalents of drugs. However, they follow different regulatory processes. The prevalence of many life-threatening diseases, such as cancer, Multiple Sclerosis (MS), and HIV, has increased regionally, which is expected to result in a rise in the need for specialized pharmaceuticals. For a variety of medication delivery methods, including intravenous, intradermal, intramuscular, intraperitoneal, subcutaneous, and others, specialty generic injectables are used to treat ailments ranging from cancer to autoimmune disorders.
During drug injection, a chemical is injected into the bloodstream using a hollow hypodermic needle. Oncology, autoimmune disorders, infectious diseases, and other indications are treated using specialty generics, which are sold through a variety of channels, including specialty pharmacies, retail pharmacies, and hospital pharmacies. Due to specific production needs, greater capital costs, and generally lower quantities as a result of a smaller patient population, specialized generics have a more competitive market than regular generics. This leads to better profits than standard generics and a lesser price drop relative to branded medicine. Since specialty generics are given by unique players, they typically require prior authorization in the market and special handling, administration, and monitoring.
The American Cancer Society reports that in 2018, there were roughly 154,050 lung cancer-related deaths in the United States, with an estimated 234,030 new cases of lung cancer being diagnosed. According to the American Lung Association, 541,000 Americans have received a lung cancer diagnosis at some time in their lives. The majority of patients have received a lung cancer diagnosis during the last five years. Each year, non-small cell lung cancer (NSCLC) is treated in tens of thousands of Americans. The market is expected to grow as a result of lung cancer's increasing prevalence. Because of the increase in cancer incidence, there is a greater need for products such as specialty generics, which boosts the regional market.
The US market dominated the North America Specialty Generics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $33,131.9 million by 2030. The Canada market is exhibiting a CAGR of 11.5% during (2023-2030). Additionally, The Mexico market should witness a CAGR of 10.5% during (2023-2030).
Based on Type, the market is segmented into Injectables, Oral Drugs, and Others. Based on Application, the market is segmented into Inflammatory conditions, Multiple sclerosis, Hepatitis C, Oncology, and Others. Based on End-use, the market is segmented into Specialty Pharmacy, Retail Pharmacy, and Hospital Pharmacy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Teva Pharmaceuticals Industries Ltd., Novartis AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Dr. Reddy’s Laboratories Ltd., Mallinckrodt PLC, Bausch Health Companies, Inc., Viatris, Inc. and Apotex, Inc.
The complex or high-end specialty generics are generic equivalents of drugs. However, they follow different regulatory processes. The prevalence of many life-threatening diseases, such as cancer, Multiple Sclerosis (MS), and HIV, has increased regionally, which is expected to result in a rise in the need for specialized pharmaceuticals. For a variety of medication delivery methods, including intravenous, intradermal, intramuscular, intraperitoneal, subcutaneous, and others, specialty generic injectables are used to treat ailments ranging from cancer to autoimmune disorders.
During drug injection, a chemical is injected into the bloodstream using a hollow hypodermic needle. Oncology, autoimmune disorders, infectious diseases, and other indications are treated using specialty generics, which are sold through a variety of channels, including specialty pharmacies, retail pharmacies, and hospital pharmacies. Due to specific production needs, greater capital costs, and generally lower quantities as a result of a smaller patient population, specialized generics have a more competitive market than regular generics. This leads to better profits than standard generics and a lesser price drop relative to branded medicine. Since specialty generics are given by unique players, they typically require prior authorization in the market and special handling, administration, and monitoring.
The American Cancer Society reports that in 2018, there were roughly 154,050 lung cancer-related deaths in the United States, with an estimated 234,030 new cases of lung cancer being diagnosed. According to the American Lung Association, 541,000 Americans have received a lung cancer diagnosis at some time in their lives. The majority of patients have received a lung cancer diagnosis during the last five years. Each year, non-small cell lung cancer (NSCLC) is treated in tens of thousands of Americans. The market is expected to grow as a result of lung cancer's increasing prevalence. Because of the increase in cancer incidence, there is a greater need for products such as specialty generics, which boosts the regional market.
The US market dominated the North America Specialty Generics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $33,131.9 million by 2030. The Canada market is exhibiting a CAGR of 11.5% during (2023-2030). Additionally, The Mexico market should witness a CAGR of 10.5% during (2023-2030).
Based on Type, the market is segmented into Injectables, Oral Drugs, and Others. Based on Application, the market is segmented into Inflammatory conditions, Multiple sclerosis, Hepatitis C, Oncology, and Others. Based on End-use, the market is segmented into Specialty Pharmacy, Retail Pharmacy, and Hospital Pharmacy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Teva Pharmaceuticals Industries Ltd., Novartis AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Dr. Reddy’s Laboratories Ltd., Mallinckrodt PLC, Bausch Health Companies, Inc., Viatris, Inc. and Apotex, Inc.
Scope of the Study
By Type
- Injectables
- Oral Drugs
- Others
By Application
- Inflammatory conditions
- Multiple sclerosis
- Hepatitis C
- Oncology
- Others
By End-use
- Specialty Pharmacy
- Retail Pharmacy
- Hospital Pharmacy
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Teva Pharmaceuticals Industries Ltd.
- Novartis AG
- Hikma Pharmaceuticals PLC
- Sun Pharmaceutical Industries Ltd.
- Fresenius SE & Co. KGaA
- Dr. Reddy’s Laboratories Ltd.
- Mallinckrodt PLC
- Bausch Health Companies, Inc.
- Viatris, Inc.
- Apotex, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. North America Specialty Generics Market by Type
Chapter 5. North America Specialty Generics Market by Application
Chapter 6. North America Specialty Generics Market by End Use
Chapter 7. North America Specialty Generics Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Teva Pharmaceuticals Industries Ltd.
- Novartis AG
- Hikma Pharmaceuticals PLC
- Sun Pharmaceutical Industries Ltd.
- Fresenius SE & Co. KGaA
- Dr. Reddy’s Laboratories Ltd.
- Mallinckrodt PLC
- Bausch Health Companies, Inc.
- Viatris, Inc.
- Apotex, Inc.
Methodology
LOADING...
